| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2020 | Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, et al. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology. 130: 109170. PMID 32777736 DOI: 10.1016/J.Ejrad.2020.109170 | 0.31 | |||
| 2020 | Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Science Advances. 6: eaaz6162. PMID 32195353 DOI: 10.1126/Sciadv.Aaz6162 | 0.319 | |||
| 2020 | Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, et al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports. 10: 3080. PMID 32080210 DOI: 10.1038/S41598-020-58366-Z | 0.368 | |||
| 2020 | Abuhadra N, Hess K, Litton J, Rauch G, Thompson A, Lim B, Adrada B, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy R, et al. Abstract P1-10-20: Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-10-20 | 0.316 | |||
| 2019 | Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, et al. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer (Amsterdam, Netherlands). PMID 31445783 DOI: 10.1016/J.Lungcan.2019.08.017 | 0.308 | |||
| 2019 | Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, et al. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct020 | 0.361 | |||
| 2019 | Hegde A, Huang L, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Simon G, Blumenschein G, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers Cancer Research. 79: 4997-4997. DOI: 10.1158/1538-7445.Am2019-4997 | 0.381 | |||
| 2019 | Sen S, Pestana RC, Hess K, Hong DS, Subbiah IM, Conley A, Falchook GS, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Abstract 3997: Outcomes of geriatric sarcoma patients enrolled in phase 1 clinical trials Cancer Research. 79: 3997-3997. DOI: 10.1158/1538-7445.Am2019-3997 | 0.351 | |||
| 2019 | Crespo J, Sahil S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada B, Rauch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Abstract 1409: Characterization of the LAR subtype triple negative breast cancer population Cancer Research. 79: 1409-1409. DOI: 10.1158/1538-7445.Am2019-1409 | 0.368 | |||
| 2019 | Majd N, Mastall M, Hess K, Fuller G, Alfaro-Munoz K, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg DI, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, et al. RARE-47. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA; A RETROSPECTIVE REVIEW OF 200 PATIENTS AT MD ANDERSON CANCER CENTER Neuro-Oncology. 21: vi231-vi232. DOI: 10.1093/Neuonc/Noz175.1191 | 0.348 | |||
| 2019 | Grant S, Lei X, Hess K, Smith G, Matin S, Wood C, Karam J, Smith B, Nguyen Q, Frank S, Anscher M, Tang C. Stereotactic Body Radiotherapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison with Surgery, Tumor Ablation, and Observation International Journal of Radiation Oncology*Biology*Physics. 105: E254-E255. DOI: 10.1016/J.Ijrobp.2019.06.1952 | 0.302 | |||
| 2018 | Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, et al. Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. Oncotarget. 9: 33258-33270. PMID 30279957 DOI: 10.18632/Oncotarget.25947 | 0.374 | |||
| 2018 | Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 9: 33232-33243. PMID 30237864 DOI: 10.18632/Oncotarget.26075 | 0.381 | |||
| 2018 | Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, et al. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer (Amsterdam, Netherlands). 120: 137-141. PMID 29748008 DOI: 10.1016/J.Lungcan.2018.03.020 | 0.339 | |||
| 2018 | Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer. PMID 29695765 DOI: 10.1038/S41416-018-0068-Z | 0.333 | |||
| 2018 | Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, et al. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 29668571 DOI: 10.1097/CJI.0000000000000222 | 0.346 | |||
| 2018 | Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Research : Bcr. 20: 27. PMID 29661243 DOI: 10.1186/S13058-018-0945-7 | 0.341 | |||
| 2018 | Hui D, Hess K, Dibaj SS, Arthur J, Dev R, Dalal S, Reddy S, Bruera E. The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer. PMID 29469951 DOI: 10.1002/Cncr.31312 | 0.303 | |||
| 2018 | Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, et al. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer. PMID 29462132 DOI: 10.1038/Bjc.2017.480 | 0.335 | |||
| 2018 | Yam C, Santiago L, Candelaria R, Adrada B, Rauch G, Hess K, Litton J, Piwnica-Worms H, Mittendorf E, Ueno N, Lim B, Murthy R, Damodaran S, Helgason T, Huo L, et al. Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-03-05 | 0.301 | |||
| 2018 | Sen S, Hong DS, Hess K, Meric-Bernstam F, Subbiah V. Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A199 | 0.316 | |||
| 2018 | Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong D, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, et al. Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer) Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A096 | 0.353 | |||
| 2017 | Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. Journal For Immunotherapy of Cancer. 5: 100. PMID 29254498 DOI: 10.1186/S40425-017-0301-Y | 0.319 | |||
| 2017 | Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 8: 58709-58727. PMID 28938590 DOI: 10.18632/Oncotarget.17634 | 0.322 | |||
| 2017 | Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, et al. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. PMID 28430579 DOI: 10.18632/Oncotarget.16840 | 0.358 | |||
| 2017 | Báez-Vallecillo L, Raghavendra AS, Hess K, Moulder S, Tripathy D, Valero V, Murthy R. Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-21-20 | 0.356 | |||
| 2017 | Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno N, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans W. Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-22 | 0.376 | |||
| 2017 | Litton J, Moulder S, Helgason T, Clayborn A, Rauch G, Gilcrease M, Adrada B, Huo L, Hess K, Symmans W, Thompson A, Tripathy D, Mittendorf E. Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-14 | 0.367 | |||
| 2017 | Sen S, Hess K, Hong D, Naing A, Piha-Paul S, Janku F, Fu S, Liu H, Jiang Y, Khanji R, Karp D, Tsimberidou A, Tannir N, Meric-Bernstam F, Subbiah V. Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials Cancer Research. 77: 3291-3291. DOI: 10.1158/1538-7445.Am2017-3291 | 0.381 | |||
| 2016 | Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, et al. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. PMID 27802448 DOI: 10.1159/000449505 | 0.369 | |||
| 2016 | Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs. PMID 27687047 DOI: 10.1007/S10637-016-0395-Y | 0.317 | |||
| 2016 | Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, Bisberg AJ, Schultz A, Engquist E, Liu L, Lin X, Chen GM, Xie H, Hunter GA, Boutros PC, et al. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. Plos Computational Biology. 12: e1004890. PMID 27351836 DOI: 10.1371/Journal.Pcbi.1004890 | 0.344 | |||
| 2016 | Tang C, Liao Z, Hess K, Chance WW, Zhuang Y, Jensen G, Xu T, Komaki R, Gomez DR. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncologica (Stockholm, Sweden). 1-7. PMID 27055359 DOI: 10.3109/0284186X.2016.1154602 | 0.313 | |||
| 2016 | George G, Buford A, Hess K, Piha-Paul S, Zinner R, Subbiah V, Iwuanyanwu E, Cleeland C, Meric-Bernstam F, Bernstam E, Hong D. Cancer-related internet use in patients with advanced cancer in a phase I clinical trials clinic European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32782-4 | 0.339 | |||
| 2015 | Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? Journal of Neurosurgery. 1-12. PMID 26495941 DOI: 10.3171/2015.5.Jns142087 | 0.303 | |||
| 2015 | Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113: 1003-9. PMID 26393887 DOI: 10.1038/Bjc.2015.308 | 0.361 | |||
| 2015 | Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22: 431-41. PMID 25900182 DOI: 10.1530/Erc-15-0002 | 0.317 | |||
| 2015 | Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7: 29. PMID 25806091 DOI: 10.1186/S13148-015-0065-5 | 0.328 | |||
| 2015 | Hu X, Martinez E, Zheng S, Barthel F, Jiang T, Hess K, Verhaak R. GENO-18A 35 GENES SIGNATURE FOR PREDICTING OUTCOME IN GLIOMA PATIENTS WITH 1p/19q CODEL Neuro-Oncology. 17: v95.2-v95. DOI: 10.1093/Neuonc/Nov215.18 | 0.333 | |||
| 2014 | Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293 | 0.336 | |||
| 2014 | de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clinical Breast Cancer. 14: 468-74. PMID 25065564 DOI: 10.1016/J.Clbc.2014.06.001 | 0.363 | |||
| 2014 | Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5: 1837-45. PMID 24742823 DOI: 10.18632/Oncotarget.1828 | 0.362 | |||
| 2014 | Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. Plos One. 9: e89388. PMID 24586741 DOI: 10.1371/Journal.Pone.0089388 | 0.348 | |||
| 2014 | Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook G, Piha-Paul S, Zinner R, Rodriguez-Canales J, He G, Siddik ZH, Jelinek J, Chung W, Ye Y, Said R, ... Hess K, et al. Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct201 | 0.312 | |||
| 2014 | Tang C, Jardim D, Gagliato D, Falchook G, Hess K, Fu S, Wheler J, Zinner R, Naing A, Tsimberidou A, Meric-Bernstam F, Hong D. Abstract 4424: Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic Cancer Research. 74: 4424-4424. DOI: 10.1158/1538-7445.Am2014-4424 | 0.391 | |||
| 2013 | Abdelrahim M, Naing A, Dalal S, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Abstract B82: Olanzapine for cachexia in patients with advanced cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B82 | 0.32 | |||
| 2011 | Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. 129: 451-8. PMID 21710134 DOI: 10.1007/S10549-011-1645-5 | 0.371 | |||
| 2011 | Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2387-93. PMID 21406473 DOI: 10.1093/Annonc/Mdq786 | 0.359 | |||
| 2009 | Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. Cancer Research. 69: 101-101. DOI: 10.1158/0008-5472.Sabcs-09-101 | 0.351 | |||
| 2007 | Lecocke M, Hess K. An empirical study of univariate and genetic algorithm-based feature selection in binary classification with microarray data. Cancer Informatics. 2: 313-27. PMID 19458774 | 0.684 | |||
| 2006 | Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. Journal of Neuro-Oncology. 78: 85-90. PMID 16391896 DOI: 10.1007/S11060-005-9062-4 | 0.365 | |||
| 2006 | Lecocke M, Hess K. An Empirical Study of Univariate and Genetic Algorithm-Based Feature Selection in Binary Classification with Microarray Data Cancer Informatics. 2: 313-327. DOI: 10.1177/117693510600200016 | 0.678 | |||
| 2005 | Yao JC, Ng C, Hoff PM, Phan AT, Hess K, Chen H, Wang X, Abbruzzese JL, Ajani JA. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4007. PMID 27944334 DOI: 10.1200/Jco.2005.23.16_Suppl.4007 | 0.312 | |||
| 2005 | McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, ... ... Hess K, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 104: 1468-77. PMID 16088966 DOI: 10.1002/Cncr.21338 | 0.303 | |||
| 2005 | Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/S10637-005-1444-0 | 0.334 | |||
| 2004 | Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 503. PMID 28016109 DOI: 10.1200/Jco.2004.22.14_Suppl.503 | 0.337 | |||
| 2002 | Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, et al. Treatment outcomes of resected esophageal cancer. Annals of Surgery. 236: 376-84; discussion 3. PMID 12192324 DOI: 10.1097/00000658-200209000-00014 | 0.348 | |||
| 2001 | Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro-Oncology. 3: 167-73. PMID 11465397 DOI: 10.1093/Neuonc/3.3.167 | 0.354 | |||
| 2001 | Kozuch P, Hoff PM, Hess K, Adams RNJ, Newman RA, Lee F, Pazdur R. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 91: 815-821. PMID 11241251 DOI: 10.1002/1097-0142(20010215)91:4<815::Aid-Cncr1069>3.0.Co;2-J | 0.331 | |||
| Show low-probability matches. | |||||